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ABSTRACT 
 
Human rhinoviruses (HRVs), causative agents for over half of cold and cold like 
illnesses, also responsible for huge economic loss as it leads to loss in working 
hours. Our enhanced understanding of the complex genomic structure of the virus 
has been a direct result of advances in molecular methods and has resulted in 
characterization of three genetically distinct HRV groups, designated groups A, B, 
and C, within the genus Enterovirus and the family Picornaviridae. The HRV 
caused common cold is one of the most widespread viral infections for which no 
substantial treatment is available till now as there exists more than 100 serotypes of 
this virus. Research solutions so far have focused on targeting the conserved capsid 
proteins and the lipids for manufacture of viral membranes. I aim to target the viral 
RNA replication inside the host by finding a lead molecule obtained from any plant 
with any known antiviral property; which would bind to the Rdrp (RNA dependent 
RNA polymerase) site of the virus and hence stop RNA replication from taking 
place. To achieve this first a library of all the phytochemicals obtained from all the 
plants having antiviral properties is prepared. Using in silico approach, the 
phytochemicals are screened for toxicity and then the lead molecule having the 
highest affinity for the virus is found. Once the lead molecule it identified, Lead 
optimization is performed which can be used to manufacture a desired drug. Also 
some structural dynamics analysis are performed on the virus along with the lead 
molecule and also compared with the structural dynamics of other structural 
proteins of the body. 
Keywords: Human Rhinovirus, phytochemicals, lead molecule, docking, 
structural dynamics 
 
  
 
 
 
 
 
 
 
CHAPTER 1 
INTRODUCTION AND LITERATURE 
REVIEW 
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1.1 INTRODUCTION 
HRV, while once only thought to be the causative agent for relatively benign 
upper respiratory tract illness; it is now explained to have connections to 
exacerbations of chronic pulmonary disease, asthma development, and, more 
recently, fatal pneumonia in elderly and immune-compromised adults as well 
as severe bronchiolitis in infants and children. A recent advance in molecular 
methods has led to better understanding of the illness spectrum of HRVs which 
has led to the efficient characterization and detection of HRV strains and 
groups. Multiplex PCR-based assays for respiratory viruses detection that 
include HRVs are being adopted by quite an increasing number of clinical 
laboratories. Currently, there are no approved antiviral agents for HRV 
infection prevention or treatment. In natural setting drug toxicities, drug 
interactions, and a lack of efficacy have limited clinical trials of antiviral 
therapies when applied. There exists too much variability for over 100 
serotypes at the antigenic sites, as a result of which the vaccine development 
has been hampered. Thus, the HRV infection treatment focuses mainly on 
symptoms relief and psychological consolation. 
  
Fig 1. 
 
  
1.1.1 Infection pathway for Rhinovirus: 
 
Fig. 2 
HRVC- The third species of HRV, recently identified, whose pathogenesis is still 
largely unknown and yet to be discovered. 
LDLR- The low density lipoprotein receptor (LDLR) gene family is made up of 
cell surface proteins which are involved in receptor-mediated specific ligands 
endocytosis. 
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ICAM 1- (Intercellular Adhesion Molecule 1) a cell surface glycoprotein encoded 
by this gene is typically expressed on immune system and endothelial cells. It 
binds to type CD11a / CD18, or CD11b / CD18 intigrins and is also serves as 
receptor to Rhinovirus. 
TLR2- This gene codes a protein which is a member of the Toll-like receptor 
(TLR) family that plays the most important role in innate immune activation and 
pathogen recognition.  Pathogen-associated molecular patterns (PAMPs) are 
recognized that are expressed on infectious agents, and the production of cytokines 
is mediated which is necessary for the effective immunity development. Most 
abundantly expressed in peripheral blood leukocytes, this gene mediates host 
response to yeast and Gram-positive bacteria via NF-kappaB simulation. 
 TLR3- Mostly expressed in pancreas and placenta, this receptor is limited to the 
dendritic subpopulation of the leukocytes.Viral infection associated dsRNA is 
recognized by it, and  it also induces the activation of NF-kappaB and the 
production of type I interferons. This gene uses alternative polyadenylation sites 
for generation of different length transcripts. 
 TLR7- This gene is most notably expressed in placenta, spleen, and lungs, and on 
chromosome X it lies in close proximity to TLR8. 
 MyD88- myeloid differentiation primary response 88: This gene encodes a 
cytosolic adapter protein which plays the main role in the adaptive and innate 
immune response. This protein works as a necessary signal transducer in the Toll-
like receptor and interleukin-1 signaling pathways. These pathways regulate that 
activation of a number of  pro-inflammatory genes. The encoded protein consists 
of an N-terminal death domain and a C-terminal Toll-interleukin1 receptor domain. 
 Increased susceptibility to pyogenic bacterial infections is a symptom of patients 
with a defect in this gene.  
 TIRAP/MAL- The TIR adaptor protein is encoded by this gene which is involved 
in the TLR4 signaling pathway of the immune system. It activates MAPK1, 
MAPK3, NF-kappa-B and JNK, that then results in inflammatory response 
followed by cytokine secretion.  
 NFκβ- nuclear factor of kappa light polypeptide gene enhancer in B-cells: 
 NFKB, activated by various extra and intra-cellular stimuli such as ultraviolet 
irradiation, cytokines, oxidant-free radicals, and viral or bacterial products is a 
transcription regulator. Activated NFKB stimulates the expression of genes 
involved in a wide variety of biological functions by translocating into the nucleus.  
 RIG1/MDA5 - RIG-I (retinoic-acid-inducible protein 1, also known as Ddx58) 
and MDA-5 (melanoma-differentiation-associated gene 5, also known as Ifih1 or 
Helicard) sense double-stranded RNA (dsRNA), a replication intermediate for 
RNA viruses, leading to production of type I interferons (IFNs) in infected cells.  
Viral dsRNA is also recognized by Toll-Like receptor 3 (TLR3) which is 
expressed on the cell surface membrane or endosomes. 
Recognition of dsRNA by RIG-I/MDA-5 or TLR3 is cell-type dependent.  
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1.1.2 Infection mechanism 
 
Fig 3. 
Once the virus enters the human body and infects the endosome, the capsid coating 
of the virus is removed by the change in pH and the negative RNA strands are 
exposed. These ssRNA translate to give rise to capsid proteins for the manufacture 
of viral capsid. Simultaneously the ssRNA replicates to form more copies of the 
RNA. 
The capsids thus manufactured and the replicated RNA molecules undergo 
assembly and packing to form new viruses exactly similar to the one that started 
the infection. Thus the reaction continues like this and more number of virus 
particles are produced.   
 1.2 LITERATURE REVIEW 
 
1.2.1 Immunity against the conserved domains of the RV family: No common 
conserved regions between species A and B have been found but within 
both the species three highly conserved domains have been identified 
which include amino acids 1–191 and 243–297 in the N-terminus of the 
polyprotein, the C-terminal domain of the RNA polymerase and VP0. 
VP0 is the natural precursor of the two N- terminus regions which lie 
within the VP4 and VP2 capsid proteins. The scientists adopted a T 
helper1/T cytokine 1 oriented response against the viral infection caused 
by this VP0 for a better disease outcome. They suggest that the Th1 cell 
responses to HRV will prove a safe strategy for preventing HRV 
induced disease which awaits confirmation in a clinical trial. 
 
1.2.2 The capsid proteins of all the serotypes of the HRV were analysed and 
the protein VP1 was found to contain highly conserved domains in all 
the serotypes. According to the same alignment, Individual ICAM-1 
footprint amino acids, which earlier were suggested to play an important 
role in virus–receptor interactions, were found out not to be conserved.. 
Whereas, amino acid residues corresponding to the documented ICAM-1 
footprint showed classification of the two receptor groups 
unequivocally. A number of similarity and divergence was found in the 
amino acid sequences found in the hydrophobic pocket of the VP1 
capsid protein. 
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1.2.3 Roulin et al showed that rhinovirus replication depends on host factors 
driving phosphatidylinositol 4-phosphate (PI4P)-cholesterol counter-
currents at viral replication membranes. Depending on the type of virus, 
replication required phosphatidylinositol 4-kinase class 3beta (PI4K3b), 
cholesterylesterasehormone-sensitive lipase (HSL) or oxysterol-binding 
protein (OSBP)-like 1, 2, 5, 9 or 11 associated with lipid droplets, 
endosomes or Golgi. Replication invariably required OSBP1, which 
shuttles cholesterol and PI4P between ER and Golgi at membrane 
contact sites. Infection also required ER-associated PI4P phosphatase 
Sac1 and phosphatidylinositol (PI) transfer protein beta (PITPb) 
shunting PI between ER-Golgi. These data support a PI4P-cholesterol 
counter-flux model for rhinovirus replication.They present evidence for 
a lipid counter-current model boosting rhinovirus infection. High 
concentrations of phosphatidyl-inositol (PI) 4-phosphate are built-up on 
Golgi membranes and used by oxysterol-binding protein-1, a sterol-
dependent transducer in cytokine signaling to load cholesterol onto viral 
replication membranes at ER-Golgi contact sites using lipid droplet 
cholesteryl-esters. 
 
 
 
 
 
 
 
 
 
  
1.3 The Rhinovirus structure used for the experiment: 
 
Fig 4.Rhinovirus 16 polymerase elongation complex (r1_form) 
 
A vital role in the growth of RNA viruses is played by RNA dependent RNA 
polymerase where they are responsible for genome replication, but is done so with 
rather low fidelity which allows for the rapid adaptation to different host cell 
environments. These polymerases also act as a great target for antiviral drug 
development. However, a lack of detailed structural information about functional 
polymerase-RNA complexes and the structural changes that take place during the 
elongation cycle has hampered our understanding of fidelity determinants and also 
our drug discovery efforts. 
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CHAPTER 2 
OBJECTIVES AND WORK PLAN 
 
 
 
 
 
 
 
 2.1 OBJECTIVES: 
 
 Preparation of a database of all the phytochemicals obtained from Indian    
plants having some or the other antiviral properties. 
 Selection of the protein of interest (HRV) and performing docking with all 
the listed phytochemicals to identify the lead molecule. 
 To perform lead optimization. 
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2.2 WORKPLAN: 
 
 
 
 
 
 
 
                  
 
 
 
 
 
                          
 
 
 
Target Identification:  Obtain the X-ray 
crystallographic structure of HRV from online 
databases; Genebank/PDB 
Observe the structure and find the Rdrp active 
site of the structures using the online tool 
Uniprot. 
Library preparation: Construct a database 
of all the phytochemicals obtained from all 
plants with antiviral properties. 
Conduct In silico toxicity test for all the 
phytochemicals obtained and choose the 
ones non toxic to the host. 
Check the characteristic of the 
toxic phytochemicals and modify 
the structure as per requirement. 
Lead identification: Identify the lead molecule 
from the library using High throughput screening 
or docking all the screened phytochemicals with 
the Rdrp site of the virus. 
Select the best phytochemicals with the highest 
affinity for the respective serotypes. 
Modify the structure of the phytochemicals thus 
obtained for better binding energy and reactivity. 
Lead optimization: Optimize the phytochemicals 
using various techniques like structural dynamics 
simulations and QSAR. 
These phytochemicals are then used to 
manufacture drugs and tested in vitro; trying the 
drugs on infected human tissue culture. 
Check the ADME for the 
phytochemicals. 
  
 
 
 
 
 
 
CHAPTER 3 
MATERIALS AND METHODS 
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3.1 Sofwares required:  
1. Argus lab- for editing the structure of the protein or the ligand obtained from 
the Protein Data Bank or Uniprot. Similarly the ligand structure can be edited. 
Editing the structure such as, removing the water molecules or any other drugs 
(ligand) attached to the protein of choice etc.  
2. Chimera 1.8.1- for viewing the protein or the ligand structure or the docked 
structure. The file should be in .pdb format. This is also used as an editor when the 
construction of the ligands are done.  
3. MGL tools 1.5.6- for doing the docking of the chosen protein and ligand.  
4. Cygwin terminal- used for docking analysis. It converts the grid parameter files 
(.gpf) and docking parameter files (.dpf) into readable formats such as the .glg and 
.dlg format. Thus getting the .pdb and .pdbqt file format of the docked molecule.  
5. Other websites like Uniprot, PDB, PreADMET, PRODRG-server, PuBChem, 
KnapSack_3D, SMILES Translator (pdb to mol conversion) etc.  
6. For normal mode analysis- http://lorentz.immstr.pasteur.fr/index1.php 
7. For elastic mode analysis- http://enm.lobos.nih.gov/ 
8. For Gaussian network model analysis- 
http://ignm.ccbb.pitt.edu/GNM_Online_Calculation.htm 
9. For flexibility analysis - 
http://mmb2.pcb.ub.es/FlexServ/viewData.php?sessId=8F1A2A1E0E2F5C7B9A7
E 
 
 
 3.2 Methodology: 
 Preparation of a database of all the Indian plants with some antiviral 
property, listing all its phytochemicals  
 3.2.1 Docking 
 Get the protein for the docking study: The protein of interest is searched in 
Uniprot or Protein Data Base (PDB) and thus the required protein structure 
is downloaded in the pdb file (text) format.  If suppose we get the structure 
of our protein from the Uniprot or PDB, such that the ligand (like drugs etc.) 
is already attached to it then we can remove such ligands from our protein of 
interest by using the ArgusLab.exe software.  
 
 Also, all the water molecules are deleted so that the required protein 
structure has all the hydrophilic sites free in it. Now the protein is ready to 
be docked. 
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 Get the ligand for the docking study: Ligands are generally searched in 
different ligand search engines such as PubChem, KnapSack_3D and many 
others available. After the desired ligand is selected it is downloaded and 
thus saved in .pdb file format. To save the ligands in .pdb file format the 
PRODRG-server is used. Thus now the ligand is also ready for docking.  
 
  Dock a protein and a ligand using Autodock  
 
 3.2.2 Toxicity test 
 The toxicity of the molecules is then checked for the molecules with best 
docking results.
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 3.2.3 ADME test: Following toxicity, ADME is predicted for those 
molecules 
 
 
 3.2.4 Structural dynamic analysis 
 After the best molecule is obtained, the structural dynamics of the 
Rhinovirus bound to the best molecules is analyzed by using a number of 
online tools like EMN, MNA and GNM calculators and compared to some 
common structural proteins. 
 Also, the flexibility of the protein is analyzed using online tool flexserve. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
CHAPTER 4 
RESULTS AND DISCUSSION 
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4.1 DOCKING RESULTS: 
We performed docking of a large number of molecules from the database prepared. 
We didn’t get very favorable results from the docking analysis. Here we list the 10 
best docking results. 
Phytochemical  Source  B.E (kcal/mol) Ki(uM)  
Chebulagic acid Terminalia chebula -8.81 3.5 
Strictinin  Tea  -7.55 2.92 
D-glucoside  A.vasica  -6.69 12.46 
Pinocembrin  Honey  -6.67 12.85 
Quercitrin  F.tataricium  -6.53 16.26 
Theaflavin  Tea  -6.52 16.56 
Myricitrin  R. paviflora  -6.3 24.28 
Valine  A.vasica  -6.26 25.98 
Isovitexin  A.vasica  -6.19 29.21 
α-amyrin  A.vasica  -6.13 31.92 
Table 1. 
1. Of all the docks performed till now, Chebuagic acid is the molecule with 
the best results so far.
2. Chebulagic acid, extracted from the plant Terminalia chebula, exhibits 
greater than 50% inhibition of HBV DNA polymerase activity in vitro and 
has showed potential antiviral activity effects against duck hepatitis B 
virus. T chebula fruits show four immunodeficiency virus GA (I), type 1 
(HIV-1) integrase inhibitors and three galloyl glucoses (II-IV). It also 
shows protection of epithelial cells against influenza A virus. It also 
demonstrated therapeutic activity against herpes simplex virus both in 
vitro and in vivo tests. Tannins fromT. chebula  are effective against 
potato virus x. (Anwesa Bag et al., 2013).
 
 3. All the 10 molecules listed in the table have been proved to show some 
anti viral property against come or the other virus.  
 
4. All these listed phytochemicals are targeted to inhibit the RNA 
replication and thus stop the rhinovirus from following the entire 
pathway.  
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4.2 TOXICITY RESULTS: 
Compunds algae_at Ames test Carcino_Mouse Carcino_Rat daphnia_at hERG_inhibition 
Chebulagic 
acid 
1.45E-06 non-mutagen negative negative 0.0197525 ambiguous 
Strictinin 0.00094343 non-mutagen negative negative 0.0801163 ambiguous 
D-glucoside 0.241751 mutagen negative negative 31.0365 low risk 
Pinocembrin 0.0617865 non-mutagen negative negative 0.144608 medium risk 
Quercitrin 0.0203185 non-mutagen negative negative 0.55858 high-risk 
Theaflavin 0.00157179 non-mutagen negative negative 0.108776 high-risk 
Myricitrin 0.0143948 non-mutagen negative negative 0.632419 ambiguous 
Valine 0.128195 mutagen positive positive 2.50339 low risk 
Isovitexin 0.0252359 mutagen negative negative 0.79706 high-risk 
Alpha-amyrin 0.00143161 non-mutagen positive positive 0.00742832 low risk 
Table 2. 
Algae_at is the in vitro toxicity test performed on algae. It shows the level 
of toxic accumulation in algae if it is treated with the chemical for 2 days. 
 
Ames_test is a simple method for testing mutagenicity of a compound, 
which was suggested by Dr. Ames. It makes use of several strains of the 
bacterium Salmonella typhimurium that carry mutations in genes which are 
involved in histidine synthesis, so that histidine is required by them for 
growth. The variable being tested shows the mutagen’s ability to cause a 
reversion to growth on a histidine-free medium. 
 
Carcino_Mouse: 2 years carcinogenicity bioassay in mouse. 
 
Carcino_Rat: 2 years carcinogenicity bioassay in rat. 
 
Daphnia_at: Acute daphnia(fish) toxicity. 
 
 
 
 hERG_inhibition: in vitro Human ether-a-go-go related gene channel 
inhibition. The protein product of the human ether-a-go-go gene (hERG) is a 
potassium channel which when inhibited by some drugs may lead to cardiac 
arrhythmia. Inhibition of the cardiac human ether-a-go-go-related gene 
channel is a major safety liability in clinical practice as it is a problematic 
off-target pharmacological activity.  
 
Analysis of the toxicity: 
 Chebulagic acid, which is our best result from docking studies, shows 
good results for the toxicity test. It shows the lowest levels of toxicity 
in the algae test. Ames test shows it to be a non mutagen and its non 
toxic to both mouse and rat tests. Also, it shows very low toxic 
accumulation in daphnia. But, it shows ambiguous results for hERG 
inhibition, which means it may or may not present a risk to the 
humans. There are chances, if administered into the human body it 
might inhibit the potassium channel and lead to cardiac arrhythmia. 
 Of all the molecules, D-glucoside, valine and alpha-amyrin show the 
lowest risk to cause human cardiac arrhythmia but D-glucoside and 
valine are found to be mutagens in the Ames test. Also, valine and 
alpha-amyrin are found to be carcinogens in the mouse and rat 
bioassays. 
 Only one molecule with medium risk to hERG inhibition is found to 
be Pinocembrin. It shows good results for all the tests. Also, the 
Ames test shows it to be a non-mutagen. Thus, Pinocembrin is the 
best molecule found in the toxicity test. 
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 Chebulagic acid, strictinin and myricitrin show extremely low levels 
of toxicity in all the tests but are ambiguous when it comes to the 
hERG inhibition test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4.3 ADME RESULTS: 
Molecules BBB Caco2 HIA MDCK Plasma_Protein_Binding Skin_Permeability 
Chebulagic acid 0.06630
31 
17.696 0 0.043415
5 
100 -2.92384 
Strictinin 0.02952
05 
12.8541 0.82218
4 
0.099712
3 
100 -4.32686 
D-glucoside 0.05938
6 
2.56748 22.3550
5 
0.655125 7.312029 -5.30926 
Pinocembrin 0.90750
3 
2.47438 92.3541
4 
43.0464 98.454853 -3.40499 
Quercitrin 0.03695
4 
7.37247 24.9475
2 
1.81906 64.952873 -4.64502 
Theaflavin 0.03560
3 
14.8721 26.2274
1 
0.044782
8 
100 -4.48468 
Myricitrin 0.03342
8 
6.14008 11.6464 1.52579 65.37898 -4.71467 
Valine 0.41087
8 
20.0466 75.2550
8 
7.36034 88.619012 -3.41617 
Alpha-amyrin 20.9638 47.1744 100      
1.43045 
100 -2.10144 
Table 3 
AD prediction interpretation 
  
There are several methods used in drug selection process to check for intestinal 
absorbtion. Caco-2 model and MDCK cell are referred to as in vitro model for 
prediction of drug absorbtion, where the drug has been administered orally. 
PreADMET predicts the permeabilty of Caco-2 cell, MDCK cell, blood brain 
barrier, Human intestianl absorption, skin permeability and plasma protein binding. 
  
Caco-2 cells are derived from human colon adenocarcinoma which has multiple 
drug transport pathways. 
  
Caco-2 permeability in PreADMET  is classified into three classes. 
  
1.  Permeability<4, then the molecule is having low permeability. 
2.  4<permeability<70, then the molecule is having medium permeability. 
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3.  Permeability>70, then the molecule is having higher permeability. 
  
 
MDCK cell permeability 
  
MDCK cell refers to Madin-Darby canine kidney cell. Since MDCK cells life span 
is less than the life span of Caco-2 cells, correlation between them is said to be 
high. MDCK cell system can be used as a good tool for rapid permeability 
screening. 
  
MDK cell level of permeability in PreADMET can be classified into three classes, 
  
1. permebiality<25= molecule has low permeability. 
2. 25<Permebiality<500= molecule has medium permeability. 
3.       Permebiality>500=  molecule has higher permeability. 
  
Human intestinal absorption  
  
The intestinal absorption is very important to find the potential candidate and 
PreADMET finds the absorption in percentage. Poorly absorbed compounds return 
0 to 20%, moderately absorbed compounds return 20- 70% and well absorbed 
compounds return 70-100%. 
 
 
 
  
 
 
 Skin permeability 
 Skin permeability factor is very important in case of cosmetics for transdermal 
delivery of drugs. PreADMET predicts the in vitro skin permeability and the result 
is given as logKp. 
  
Blood Brain Barrier 
  
It predicts whether compounds passes across the blood-brain barrier or not as it is 
crucial in the pharmaceutical sphere because CNS-active compounds are the only 
substances which must cross the barrier. In PreADMET, one can predict rates for 
BBB penetration in vivo data. 
  
PreADMET explains about the absorbtion to CNS as follows. 
 
  
Table 4:  Absorption level in central nervous system 
  
Plasma protein binding of a drug gives information on the drug action, deposition 
and efficacy. 
  
In PreADMET, plasma protein binding capacity is referred to as 
 
Table 5 
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ADME RESULT ANALYSIS: 
 The best molecule of our docking result i.e., chebulagic acid, shows 
medium absorption to the human colon. It has low absorption in the 
kidney thus, can be easily excreted from the body. But, this molecule 
shows no absorption in the intestine which is not favorable for a drug. 
It shows very low permeability through the skin and strongly bound 
to the plasma but it also shows very low absorption to the CNS. 
 
 Our best result from the toxicity test i.e., Pinocembrin shows medium 
absorption to the CNS and low absorption to the colon. It is very well 
absorbed by the intestines and shows medium absorption to the 
kidney. It is strongly bound to the plasma protein and has very low 
permeability to the skin. Thus, overall it shows very good result in the 
ADME test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 LEAD OPTIMIZATION: PROTEIN STRUCTURAL DYNAMICS 
RESULTS: 
Proteins usually are dynamic molecules and keep on changing with time and 
residue. They have inherent flexibility which allows them to modify as required 
and interact with a number of molecules. Proteins owe their various 
conformational changes and response towards different molecules, to their 
dynamic nature. 
The protein structural analysis is done using a number of online tools which give 
the Normal mode analysis, the elastic network mode analysis, Gaussian normal 
mode analysis and flexibility of the protein along each residue. 
The normal mode analysis shows the change in the residue at every node. The 
entire protein is analyzed for a specific time period and nodes are specific time 
instances considered at which the analysis is done for each residue of the protein. 
Resultantly we get the conformational changes in protein at specific point of time. 
The elastic network model is the harmonic approximation of free surface energy of 
the protein near to its stable conformation. It describes the low frequency collective 
motions in the protein.  
CC plots obtained from the Gaussian network model gives the cross correlations 
among the fluctuations in the residues. The values vary from +1 to -1. 
+1 : red coloured. Shows that the fluctuation vectors are in the same direction also 
in the same sense. 
-1 : dark blue coloured. Shows that the fluctuation vectors are in the same direction 
but in the opposite sense. 
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 Here we first compute the flexibility of the HRV protein used to 
perform the experimentation.  
 We then perform the structural dynamics simulation of the rhinovirus 
and compare it with four structural proteins i.e. collagen 1, collagen 
9, keratin and silk fibroin. 
 By comparing we can find the structural similarity of the rhinovirus 
with the structural proteins in the body and thus can find the physical 
strength of the rhinovirus. 
 We then carry out the structural dynamic simulations of the 
rhinovirus bound to the 10 best ligands obtained earlier and analyze 
what effect these ligands have on the physical properties of the 
protein. 
 We also compare the ligand bound protein to the structural proteins to 
find out if there is any similarity exists because when treating the 
virus with the ligands we have to make sure that the structural 
proteins of our body are not affected. 
 
 
 
 
 
 
 
 
 
 Variance profile: 
 
Dimensionality/Quality profile 
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Size of essential space  38 eigenvalues 
Total variance captured 147.770 Å² 
Percentage of variance captured 90.24% 
The first graph shows the total variance of the trajectory and how it is distributed 
along the different eigenvectors. This graph indicates the size of the flexibility 
space (higher the variance higher the flexibility) and how it is distributed in 
different modes. Clearly, Rhinovirus’s flexibility decreases with the higher nodes. 
The second graphic shows the percentage of explained variance for a given number 
of eigenvectors (quality) and the dimensionality of the sampled space. This graph 
indicates the complexity of the flexibility space, i.e. how many modes are 
necessary to explain the entire flexibility of the protein. Note that both the graphs 
provide physically-different information and that proteins might display a very 
complex pattern of flexibility (leading to large dimensionality) and at the same 
time be quite rigid (low variance), or have a large variance which can be fully 
explained by a very small number of modes. For HRV, the number of nodes 
required to explain the flexibility increases as the number of residues increases. 
 
 
 
 
 
 
 
 
 B factor profile: 
 
B factor determines the flexibility of the molecule. 
 
  = the oscillations of residues around equilibrium positions. 
B-factor profiles represent the distribution of residue harmonic oscillations. Very 
large-B-factors indicate very flexible residues that might display conformational 
changes along the trajectory, which is difficult to follow within the harmonic 
approximation implicit to B-factor analysis. 
Our protein shows a variety of flexibility along each residue. From this we can 
infer that our protein is a very unstable one. Some of the residues show high 
flexibility while some show very low flexibility. It indicates that the protein is 
extremely dynamic in nature and keeps on changing its overall conformation 
constantly. 
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Comparing Rhinovirus with the structural proteins: 
 
The above graphs are a result of the Gaussian network modeling and they depict 
that our viral protein shows very similar residue dynamics with collagen1 
molecules. It also shows a little similarity with keratin. But the virus protein is 
found to be extremely different from collagen 9 and silk molecules. 
In Rhinovirus, collagen 1 and keratin, majority of the residues show fluctuations in 
the same direction but in opposite sense. 
 
 
  
 
Comparing the Normal mode analysis of Rhinovirus with the selected structural 
protein showed very different result from the one obtained from the Gaussian 
network model. 
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According to the Normal Mode Analysis (NMA), the viral protein shows dynamics 
very similar to those shown by the collagen 9 molecule. It shows striking 
difference from collagen 1 molecule. 
However, continuing from the Gaussian network model, it shows very dissimilar 
results from the other two structural proteins. 
We then analyze the NMA, Elastic Network Model (ENM) and Gaussian 
network model for the Rhinovirus molecule bound to our top ligands obtained 
from the docking, toxicity and ADME test results. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chebulagic acid- Rhinovirus complex: 
Elastic Normal mode: 
 
CC plot: 
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Normal mode analysis: 
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Strictinin- Rhinovirus complex: 
Elastic normal mode: 
 
CC plot: 
 
 
 Normal Mode analysis: 
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 D-glucoside- Rhinovirus complex: 
Elastic Normal Mode: 
 
CC plot: 
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Normal mode analysis: 
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Pinocembrin- Rhinovirus complex: 
Elastic normal mode: 
 
CC plot: 
 
 
 Normal Mode analysis: 
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 Quercitrin- Rhinovirus complex: 
Elastic normal mode: 
 
CC Plot: 
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Normal mode analysis: 
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Theaflavin- Rhinovirus complex: 
Elastic normal mode: 
 
 
CC Plot: 
 
 Normal mode analysis: 
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 Myricitrin- Rhinovirus complex: 
Elastic normal mode: 
 
CC Plot: 
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Normal mode analysis: 
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Valine- Rhinovirus complex: 
Elastic Normal mode: 
 
CC Plot: 
 
 
 Normal mode analysis: 
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 Isovitexin- Rhinovirus complex: 
Elastic normal mode: 
 
 
CC Plot: 
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Normal mode analysis: 
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Alpha-amyrin Rhinovirus complex: 
Elastic normal mode: 
 
CC Plot
 
 
 Normalmode analysis: 
  
  
 
 
72 
 
 
 
  
 
 
 
 
 The structural dynamics models generated for the different 
protein-ligand complexes didn’t show any remarkable difference. 
 
  
 
 
 
 
 
 
 
 
 
 
CHAPTER 5 
CONCLUSION 
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5. CONCLUSION: 
In this project, we successfully identified a molecule which could be used 
to manufacture a drug which might provide immunity against Rhinovirus 
caused common cold i.e., Pinocembrin obtained from honey. It can stop 
the RNA replication by the virus in the host by attaching to its Rdrp site. 
 Nonetheless, before manufacturing the drug, the molecule has to be 
further optimized. It also has to undergo in vitro and in vivo testing 
before being commercially manufactured. Apart from the chemical aspect 
of the viral infection, the physical aspect was also analyzed to make sure 
that the ligand didn’t have any adverse physical effect on the body. As a 
result of which the structural dynamics of the Rhinovirus was 
successfully analyzed and compared to some of the structural proteins of 
the body and found to have similarity with collagen molecules. Hence, it 
has to be taken care of that the ligand doesn’t affect the collagen 
molecules in the body anyway when administered. However, the 
dynamics of the protein was not remarkably affected by the binding of 
different ligands. 
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